Big Tech and the digital economy
Experimental pancreatic cancer vaccine triggers an immune response in nearly 99% of patients
In a phase 2 trial, the vaccine camupepimut prompted an increased T-cell response in nearly all participants, but it did not significantly improve disease-free survival.